JP2017528117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528117A5 JP2017528117A5 JP2016575026A JP2016575026A JP2017528117A5 JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5 JP 2016575026 A JP2016575026 A JP 2016575026A JP 2016575026 A JP2016575026 A JP 2016575026A JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- multispecific antibody
- molecule according
- domain
- dsfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1411420.1 | 2014-06-26 | ||
| GBGB1411420.1A GB201411420D0 (en) | 2014-06-26 | 2014-06-26 | Antibody constructs |
| PCT/EP2015/064450 WO2015197789A1 (en) | 2014-06-26 | 2015-06-25 | Multi-specific antibody constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528117A JP2017528117A (ja) | 2017-09-28 |
| JP2017528117A5 true JP2017528117A5 (enExample) | 2018-08-02 |
Family
ID=51410201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575026A Pending JP2017528117A (ja) | 2014-06-26 | 2015-06-25 | 多重特異性抗体コンストラクト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170198062A1 (enExample) |
| EP (1) | EP3161008B1 (enExample) |
| JP (1) | JP2017528117A (enExample) |
| CN (1) | CN106459217A (enExample) |
| BR (1) | BR112016030424A2 (enExample) |
| CA (1) | CA2953638A1 (enExample) |
| ES (1) | ES2763525T3 (enExample) |
| GB (1) | GB201411420D0 (enExample) |
| RU (1) | RU2710730C2 (enExample) |
| WO (1) | WO2015197789A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6152107B2 (ja) * | 2011-09-16 | 2017-06-21 | ユセベ ファルマ ソシエテ アノニム | クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| AU2019205406A1 (en) * | 2018-01-08 | 2020-08-27 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| SG11202009804RA (en) * | 2018-04-11 | 2020-11-27 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| TW202035451A (zh) | 2018-07-24 | 2020-10-01 | 美商英伊布里克斯公司 | 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| AU2021231712A1 (en) * | 2020-03-03 | 2022-10-06 | Systimmune, Inc. | Anti-CD19 antibodies and methods of using and making thereof |
| EP4126936A1 (en) | 2020-03-27 | 2023-02-08 | UCB Biopharma SRL | Autonomous knob domain peptides |
| US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2246538C2 (ru) * | 1998-05-20 | 2005-02-20 | Чугаи Сейяку Кабусики Кайся | Способ и набор для выявления гена, кодирующего мембраносвязанный белок, вектор (варианты) |
| AR056142A1 (es) * | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| ES2667729T3 (es) * | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| CN102143977B (zh) * | 2008-09-03 | 2014-08-06 | 霍夫曼-拉罗奇有限公司 | 多特异性抗体 |
| JP2012503612A (ja) * | 2008-09-26 | 2012-02-09 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗ｅｇｆｒ／抗ｉｇｆ−１ｒ抗体 |
| CN102481367B (zh) * | 2009-07-06 | 2015-04-29 | 弗·哈夫曼-拉罗切有限公司 | 结合地高辛配基的双特异性抗体 |
| RU2013110875A (ru) * | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| PT2825559T (pt) * | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
-
2014
- 2014-06-26 GB GBGB1411420.1A patent/GB201411420D0/en not_active Ceased
-
2015
- 2015-06-25 ES ES15733415T patent/ES2763525T3/es active Active
- 2015-06-25 US US15/321,061 patent/US20170198062A1/en not_active Abandoned
- 2015-06-25 EP EP15733415.2A patent/EP3161008B1/en active Active
- 2015-06-25 RU RU2017102312A patent/RU2710730C2/ru active
- 2015-06-25 JP JP2016575026A patent/JP2017528117A/ja active Pending
- 2015-06-25 CN CN201580034555.0A patent/CN106459217A/zh active Pending
- 2015-06-25 WO PCT/EP2015/064450 patent/WO2015197789A1/en not_active Ceased
- 2015-06-25 CA CA2953638A patent/CA2953638A1/en not_active Abandoned
- 2015-06-25 BR BR112016030424A patent/BR112016030424A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528117A5 (enExample) | ||
| RU2017102312A (ru) | Конструкции мультиспецифичных антител | |
| JP2019506841A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| HRP20191775T1 (hr) | Multispecifične konstrukcije antitijela | |
| JP2014505463A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2016521688A5 (enExample) | ||
| JP2020503001A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2018527919A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2019534277A5 (enExample) | ||
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2016529215A5 (enExample) | ||
| HRP20220111T1 (hr) | Protutijela protiv pd-1 | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| JP2017184723A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| HRP20240495T1 (hr) | Anti-garp antitijelo | |
| EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
| EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
| JP2016104790A5 (enExample) |